The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki
The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki
CHAPTER 13 Prospects for Intervention T he retardation or reversal of aging has been a desire of mankind for as long as we can trace, but biologists have not worked particularly hard to achieve it. One reason for this—a very poor one, in my view—is that it is clearly a very hard problem, and therefore one on which progress is likely to be slow and patchy. A big problem with patchy progress, for the researcher, is that one’s ability to attract funds for subsequent work is always dependent upon one’s record to date, with the result that both success and failure in science tend to be self-perpetuating. NB: I call this a poor reason, but of course (a) I speak with the luxury of a theoretician, whose budget is negligible compared to those of the experimentalists whose work I study, and (b) it goes without saying that the funding regime I describe is not the fault of scientists. Therefore I certainly have sympathy with the widespread disinclination to work on very hard problems. I just don’t like it. The other main reason why manipulation of the aging process has not been a popular research field is rather better. It is that the problem is not only very hard, it is also so diffuse that people have not had much idea where to begin. If a scientist needs one thing more than any other, it is self-motivation. This is hard to sustain if one has no real confidence that success in the project immediately underway will constitute real progress towards one’s ultimate goal. And such, unfortunately, has been the situation in gerontology. We have mountains of data on what makes for a long, healthy life, but we have lacked sufficient interpretation of that data to be able to formulate a realistic plan for its exploitation to engineer an even longer one. Now, however, that psychological barrier is crumbling. In the foregoing chapters of this book, I have set out a description of how we age which, though still only hypothetical and in need of rigorous testing, is a great deal more detailed that any that have preceded it. Detail is the keystone of scientific confidence: if one describes a process only in broad terms, however plausible they may sound, others will harbour doubts that some problems have been overlooked, but if those broad terms can be broken down into lower-level parts, while retaining overall plausibility, those doubts are correspondingly assuaged. This is not a peculiarity of science—it is very much the same as the description of a mathematical proof, or the design of a large computer program. Detail is explanation, and explanation is reassurance. Moreover, as noted in the Introduction, it is a matter of opinion just how strongly confirmed by experiment a hypothesis should be before one invests significant resources in an enterprise which would be valueless if the hypothesis were wrong. The main criterion which modulates that cutoff is one’s perception of how valuable the enterprise would be if the hypothesis were right. In the case of MiFRA, many people—including, without doubt, people with the necessary skills and resources—consider that the enterprise of retarding aging is quite valuable enough to motivate investment of those resources on the basis of MiFRA’s present degree of confirmation, prior even to the undertaking of the tests discussed in Chapter 12. The only factor that has held back such work hitherto has been the presence The Mitochondrial Free Radical Theory of Aging, by Aubrey D.N.J. de Grey. ©1999 R.G. Landes Company.
166 The Mitochondrial Free Radical Theory of Aging of unsettlingly large gaps in the theoretical framework: something which, as previous chapters have discussed, is broadly a thing of the past. Consequently I shall devote this chapter to an examination of how, if the theory set out in previous chapters is indeed correct, we may in principle be able to retard human aging. The two approaches which I consider most promising will then be analysed in detail in the following chapters. 13.1. Some Probably Futile Approaches In principle, if there is indeed a single chain of events which dominates the rate at which we age, the progress of aging could be greatly retarded by breaking any link in that chain. Some such treatments might not be able to reverse aging that has already occurred, but a clean break of any link in the causal chain should put a brake on further progress. Similarly, a treatment that only weakens, rather than breaks, one of the links would still retard aging, albeit to a lesser extent. The first question one should consider, therefore, is: “Supposing (for sake of argument) that MiFRA is correct, which links in it are the most amenable to disruption?” Here are the possibilities which seem to be available. They each seek to subvert some link in the chain of events leading from mtDNA mutations to systemic oxidative stress, and are listed in causal order with respect to that chain. In theory one might extend the list to include treatments of the effects of oxidative stress, but I have avoided this because, as discussed in Section 6.5, the strong evidence from inter-species comparisons is that such “late-acting” interventions (by which is meant causally late, as opposed to late in the lifespan) are ineffective if the tide of early events is allowed to continue unabated. a. Stop the spontaneous mutation of mtDNA b. Repair spontaneous mutations of mtDNA c. Introduce extra, wild-type mtDNA into mutant mitochondria d. Stop OXPHOS from fumbling electrons and making LECs e. Stop LECs from damaging mitochondrial membranes f. Destroy mutant mtDNA before it takes over the cell g. Reverse SOS—give mutant mtDNA a selective disadvantage h. Abolish cells’ reliance on wild-type mtDNA for OXPHOS i. Abolish cells’ reliance on OXPHOS for autonomous ATP synthesis j. Kill cells that have lost OXPHOS function (have become anaerobic) k. Prevent anaerobic cells from causing the peroxidation of plasma lipids l. Prevent mitochondrially healthy cells from importing peroxidised lipids A reasonable first step in deciding which of these is most realistically addressable is to consider what the body already does. Options a, b, d, e, k and l can, I feel, be excluded from further consideration on the grounds that the human body already works very hard to achieve them, by means that have been described earlier in this book, and this work is done by genetically determined machinery that has been developed by natural selection. Humans are among the longest-lived species for our metabolic rate, so there is unlikely to be any grossly suboptimal feature of this machinery. It is possible that, by studying species which do even better than us (as has been eloquently urged by Austad) 1 we could identify some of the slightly suboptimal ones, manifest as refinements that these species have achieved, but mimicking those refinements might be impractically laborious even with the development of reliable gene therapy (which is discussed in Section 13.4). Moreover, even the most exceptional birds achieve mortality rate doubling times (see Section 17.1) only about 50% greater than ours, 1 so this approach could only retard aging by that factor; the deleterious effects of introducing such genetic changes into a genome that has evolved without them are virtually certain to outweigh that and result in no net slowdown of aging. The only way
- Page 119 and 120: The Search for How So Few Anaerobic
- Page 121 and 122: CHAPTER 10 Frequently-Asked Questio
- Page 123 and 124: Frequently-Asked Questions The effe
- Page 125 and 126: Frequently-Asked Questions Table 10
- Page 127 and 128: Frequently-Asked Questions through
- Page 129 and 130: Frequently-Asked Questions has been
- Page 131 and 132: Frequently-Asked Questions SOS, sin
- Page 133 and 134: Frequently-Asked Questions for almo
- Page 135 and 136: Frequently-Asked Questions Fig. 10.
- Page 137 and 138: Frequently-Asked Questions Fig. 10.
- Page 139 and 140: Frequently-Asked Questions of elect
- Page 141 and 142: Frequently-Asked Questions Referenc
- Page 143 and 144: Frequently-Asked Questions 45. Clay
- Page 145 and 146: CHAPTER 11 A Challenge from Textboo
- Page 147 and 148: A Challenge from Textbook Bioenerge
- Page 149 and 150: A Challenge from Textbook Bioenerge
- Page 151 and 152: A Challenge from Textbook Bioenerge
- Page 153 and 154: A Challenge from Textbook Bioenerge
- Page 155 and 156: A Challenge from Textbook Bioenerge
- Page 157 and 158: A Challenge from Textbook Bioenerge
- Page 159 and 160: A Challenge from Textbook Bioenerge
- Page 161 and 162: A Challenge from Textbook Bioenerge
- Page 163 and 164: A Challenge from Textbook Bioenerge
- Page 165 and 166: 160 The Mitochondrial Free Radical
- Page 167 and 168: 162 The Mitochondrial Free Radical
- Page 169: 164 The Mitochondrial Free Radical
- Page 173 and 174: 168 The Mitochondrial Free Radical
- Page 175 and 176: 170 The Mitochondrial Free Radical
- Page 177 and 178: CHAPTER 14 Ablation of Anaerobic Ce
- Page 179 and 180: Ablation of Anaerobic Cells: Techni
- Page 181 and 182: CHAPTER 15 Transgenic Copies of mtD
- Page 183 and 184: Transgenic Copies of mtDNA: Techniq
- Page 185 and 186: Transgenic Copies of mtDNA: Techniq
- Page 187 and 188: Transgenic Copies of mtDNA: Techniq
- Page 189 and 190: Transgenic Copies of mtDNA: Techniq
- Page 191 and 192: Transgenic Copies of mtDNA: Techniq
- Page 193 and 194: CHAPTER 16 Prospective Impact on th
- Page 195 and 196: Prospective Impact on the Healthy H
- Page 197 and 198: Prospective Impact on the Healthy H
- Page 199 and 200: 196 The Mitochondrial Free Radical
- Page 201 and 202: 198 The Mitochondrial Free Radical
- Page 203 and 204: Index Symbols “~”, 19 A Acetald
- Page 205 and 206: Index Copper 35, 107 see also trans
- Page 207 and 208: Index Heart comparison to man-made
- Page 209 and 210: Index genetic code 23, 115-118, 177
- Page 211 and 212: Index Perhydroxyl radical 41, 122,
- Page 213 and 214: Index protonation see protonation (
- Page 215: MOLECULAR BIOLOGY INTELLIGENCE UNIT
CHAPTER 13<br />
Prospects for Intervention<br />
T he retardation or reversal <strong>of</strong> aging has been a desire <strong>of</strong> mankind for as long as we can<br />
trace, but biologists have not worked particularly hard to achieve it. One reason for<br />
this—a very poor one, in my view—is that it is clearly a very hard problem, and therefore<br />
one on which progress is likely to be slow and patchy. A big problem with patchy progress,<br />
for the researcher, is that one’s ability to attract funds for subsequent work is always<br />
dependent upon one’s record to date, with the result that both success and failure in science<br />
tend to be self-perpetuating. NB: I call this a poor reason, but <strong>of</strong> course (a) I speak with the<br />
luxury <strong>of</strong> a theoretician, whose budget is negligible compared to those <strong>of</strong> the<br />
experimentalists whose work I study, and (b) it goes without saying that the funding regime<br />
I describe is not the fault <strong>of</strong> scientists. <strong>The</strong>refore I certainly have sympathy with the<br />
widespread disinclination to work on very hard problems. I just don’t like it.<br />
<strong>The</strong> other main reason why manipulation <strong>of</strong> the aging process has not been a popular<br />
research field is rather better. It is that the problem is not only very hard, it is also so diffuse<br />
that people have not had much idea where to begin. If a scientist needs one thing more<br />
than any other, it is self-motivation. This is hard to sustain if one has no real confidence<br />
that success in the project immediately underway will constitute real progress towards<br />
one’s ultimate goal. And such, unfortunately, has been the situation in gerontology. We<br />
have mountains <strong>of</strong> data on what makes for a long, healthy life, but we have lacked sufficient<br />
interpretation <strong>of</strong> that data to be able to formulate a realistic plan for its exploitation to<br />
engineer an even longer one.<br />
Now, however, that psychological barrier is crumbling. In the foregoing chapters <strong>of</strong> this<br />
book, I have set out a description <strong>of</strong> how we age which, though still only hypothetical and in<br />
need <strong>of</strong> rigorous testing, is a great deal more detailed that any that have preceded it. Detail is<br />
the keystone <strong>of</strong> scientific confidence: if one describes a process only in broad terms, however<br />
plausible they may sound, others will harbour doubts that some problems have been overlooked,<br />
but if those broad terms can be broken down into lower-level parts, while retaining<br />
overall plausibility, those doubts are correspondingly assuaged. This is not a peculiarity <strong>of</strong><br />
science—it is very much the same as the description <strong>of</strong> a mathematical pro<strong>of</strong>, or the design<br />
<strong>of</strong> a large computer program. Detail is explanation, and explanation is reassurance.<br />
Moreover, as noted in the Introduction, it is a matter <strong>of</strong> opinion just how strongly<br />
confirmed by experiment a hypothesis should be before one invests significant resources in<br />
an enterprise which would be valueless if the hypothesis were wrong. <strong>The</strong> main criterion<br />
which modulates that cut<strong>of</strong>f is one’s perception <strong>of</strong> how valuable the enterprise would be if<br />
the hypothesis were right. In the case <strong>of</strong> MiFRA, many people—including, without doubt,<br />
people with the necessary skills and resources—consider that the enterprise <strong>of</strong> retarding<br />
aging is quite valuable enough to motivate investment <strong>of</strong> those resources on the basis <strong>of</strong><br />
MiFRA’s present degree <strong>of</strong> confirmation, prior even to the undertaking <strong>of</strong> the tests discussed<br />
in Chapter 12. <strong>The</strong> only factor that has held back such work hitherto has been the presence<br />
<strong>The</strong> <strong>Mitochondrial</strong> <strong>Free</strong> <strong>Radical</strong> <strong>The</strong>ory <strong>of</strong> <strong>Aging</strong>, by Aubrey D.N.J. de Grey.<br />
©1999 R.G. Landes Company.